EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

How should we target and reduce the production of pathogenic IgA in IgAN?

Chee Kay Cheung iD, Yusuke Suzuki

Nephrology Dialysis Transplantation · 23.02.2026 · 41 (Supplement_1) · i6-i14

DOI: 10.1093/ndt/gfaf185 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 23.09.2025. Verfasst von Chee Kay Cheung und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Immunoglobulin A. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Otsuka America Pharmaceutical, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IgA nephropathy represents the most common primary glomerulonephritis worldwide and is characterized by a progressive decline in kidney function, with a large proportion of patients developing kidney failure within their lifetime. Significant progress in the understanding of its pathogenesis has led to a multi-hit model being established, where elevated levels of galactose-deficient-IgA1 (Gd-IgA1), probably from a mucosal source, are found in the circulation and recognized by autoantibodies, leading to the formation of pathogenic immune complexes that deposit within the glomerular mesangium, and subsequent inflammation and damage. Several therapies are currently being developed in IgAN that target the production of pathogenic IgA, including those directed at mucosal B cell priming, inhibitors of the B cell survival mediators APRIL and B cell activation factor, and drugs that target IgA-producing plasma cells. In this review, we describe the production of IgA and summarize the emerging clinical data arising from these strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAImmunoglobulin AHumansB-LymphocytesAnimals

Stichwörter der Autor:innen

B cellsIgA nephropathygalactose-deficient-IgA1glomerulonephritisplasma cells

Substanzen

Immunoglobulin A

Autor:innen und Institutionen

  • Mayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
  • John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.

ORCID-Profile: Chee Kay Cheung

Förderung

  • Otsuka America Pharmaceutical, Inc.

Zitieren

APA

Cheung, C. K., & Suzuki, Y. (2026). How should we target and reduce the production of pathogenic IgA in IgAN?. Nephrology Dialysis Transplantation, 41(Supplement_1), i6-i14. https://doi.org/10.1093/ndt/gfaf185

Vancouver

Cheung CK, Suzuki Y. How should we target and reduce the production of pathogenic IgA in IgAN?. Nephrology Dialysis Transplantation. 2026;41(Supplement_1):i6-i14. doi:10.1093/ndt/gfaf185

BibTeX
@article{Cheung2026,
  author = {Cheung, Chee Kay and Suzuki, Yusuke},
  title = {How should we target and reduce the production of pathogenic IgA in IgAN?},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  pages = {i6--i14},
  doi = {10.1093/ndt/gfaf185}
}
Kostenlos starten →